Ask ten people whether psilocybin is legal in the United States right now and you’ll likely get ten different answers, because the honest answer depends entirely on which state you’re standing in, and even then, the word “legal” is doing a lot of unclear work.
The Two States With Real Access
As of 2026, only two states have fully operational, regulated psilocybin access: Oregon and Colorado. Oregon was first, having approved supervised therapeutic use through a 2020 ballot measure known as Measure 109 (the Oregon Psilocybin Services Act). Colorado followed with its own Natural Medicine Health Act (Proposition 122) in 2022, which went further than Oregon’s model by also decriminalizing personal use of DMT, ibogaine, and mescaline, while separately building out a licensed healing-center system for supervised psilocybin sessions. Colorado’s first licensed healing center, The Center Origin in Denver, opened its doors in April 2025, more than two years after voters approved the measure—a gap that illustrates just how much regulatory infrastructure has to be built before a law like this becomes something an actual person can walk in and use.
New Mexico’s Different Path
New Mexico is the state to watch next. Its Medical Psilocybin Act passed the legislature in 2025, making it the first state to authorize psilocybin therapy through elected lawmakers rather than a ballot initiative—a distinction that matters politically because it suggests a path to psychedelic reform that doesn’t depend on the expensive, unpredictable process of a statewide referendum campaign. The program remains under construction, and state health officials have set a target of seeing the first patients by the end of 2026, strictly for qualifying medical conditions like treatment-resistant depression, PTSD, substance use disorders, and end-of-life care, all delivered under licensed healthcare providers rather than the more loosely structured wellness-retreat model seen elsewhere.
Decriminalization Is Not Legalization
Beyond those three states, the picture gets murkier fast. A handful of cities, including Denver and several municipalities in California, Michigan, and Massachusetts, have decriminalized personal possession of psilocybin at the local level. Decriminalization is not the same as legalization: it typically means police treat possession as a low enforcement priority, or replace criminal charges with civil ones, but it does not create any legal pathway to actually purchase, sell, or access the substance in a supervised setting.
Massachusetts offers a useful case study in how slowly this process tends to move even when there’s real legislative momentum. The state currently has a psilocybin therapy framework bill active in its 2026 legislative session, but as of this writing it remains stuck in committee (or has advanced only partially), having not yet reached a full floor vote in some versions of the process. Meanwhile, several other states including New York, New Jersey, Vermont, and Rhode Island have active legislative proposals to decriminalize or regulate natural psychedelics, though none have passed as of this writing. New York’s proposal, sponsored by Assemblymember Linda B. Rosenthal, is notable for its scope: it would legalize adult possession of a broad category of natural plant and fungus-based hallucinogens, including DMT, mescaline, and psilocybin, while also explicitly including ibogaine, a substance often left out of similar bills due to its more complex cardiac safety profile.
Federal Law Still Says No
And regardless of what any individual state does, psilocybin remains a Schedule I controlled substance under federal law, meaning federal enforcement authority technically still applies everywhere in the country, even in Oregon and Colorado. In practice, federal authorities have generally not intervened in state-level psychedelic programs the way they occasionally have with cannabis, but that restraint is a matter of enforcement priority rather than a settled legal principle, and it could shift under a different administration.
What This Actually Costs
Cost is another dimension worth flattening the hype around. Even in Oregon and Colorado, where regulated access genuinely exists, a single supervised psilocybin session at a licensed facility typically costs several hundred to over a thousand dollars once facilitator fees, preparation, and integration sessions are included—entirely out of pocket, since no insurance plan currently covers this kind of session. That price point means “legal access” in practice still functions as a service available mainly to people with significant discretionary income, a genuine equity concern that advocates in both states have raised as their programs mature.
The upshot: if you’re trying to understand where things actually stand, the safest approach is to separate three distinct questions rather than treat them as one. Is it decriminalized where you live? Is there a regulated, supervised access program? And regardless of either answer, what does federal law say? Right now, only Oregon and Colorado can answer the second question with a real yes, and New Mexico is on track to become the third.
It’s worth understanding why this patchwork approach has emerged rather than a single, coordinated national policy shift. Drug scheduling in the United States is fundamentally a federal matter, but enforcement priorities and the ability to build regulated access programs have always been left substantially to individual states—the same structural quirk that produced wildly inconsistent cannabis policy for the better part of two decades before anything resembling national coherence began to emerge. There’s also a meaningful difference in philosophy between the ballot-initiative states and the legislative states: Oregon and Colorado both arrived at their programs through direct voter initiatives, which tend to produce broader frameworks but leave significant implementation details for regulators to work out after the fact, contributing to the multi-year gap between passage and actual patient access seen in both states.
